Insider trading allegations stall Sun–Ranbaxy deal


The merger deal that would create India’s largest pharmaceutical company has been stalled by accusations of insider trading of shares in the lead-up to the takeover announcement. The High Court of Andhra Pradesh has halted the transaction between Sun Pharma and Ranbaxy while the allegations are investigated.

The allegations centre on an unusually rapid increase in Ranbaxy’s share price in the week before the deal was announced. Sun Pharma has denied any wrongdoing, saying in a statement that: ‘The matter related to purchase of shares of Ranbaxy Laboratories does not violate insider trading rules.’


Related Content

Sun Pharma snares Ranbaxy in $4bn deal

1 April 2015 Business

news image

Acquisition makes Sun biggest drug firm in India and fifth largest generics producer in the world

Sun set on Ranbaxy rescue

9 April 2014 Business

news image

Acquiring beleaguered firm will create India’s biggest pharmaceutical company

Most Read

Schott's glass

29 April 2015 Classic Kit

news image

Life through a lens

First pictures of hydrogen bonds unveiled

26 September 2013 Research

news image

Observation of intermolecular interactions in quinolines could help to settle the nature of this kind of bonding

Most Commented

Science for life: a manual for better living

1 May 2015 Review

news image

Looking beyond the hype

An unfortunate oversight

27 April 2015 Critical Point

news image

The US Toxic Substances Control Act is in dire need of reform. That demands compromises, says Mark Peplow